Curanex Pharmaceuticals (NASDAQ:CURX) Stock Price Up 1.4% – Here’s Why

Curanex Pharmaceuticals Inc (NASDAQ:CURX) rose 1.4% on Thursday . The company traded as high as $0.4904 and last traded at $0.4431. Approximately 124,579 shares were traded during trading, an increase of 4% from the average daily volume of 120,353 shares. The stock had previously closed at $0.4370.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e-)” rating on shares of Curanex Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Curanex Pharmaceuticals presently has a consensus rating of “Sell”.

Curanex Pharmaceuticals Stock Up 1.4%

The business’s 50 day moving average is $0.43 and its two-hundred day moving average is $0.46. The firm has a market cap of $12.57 million and a P/E ratio of -2.61.

Curanex Pharmaceuticals (NASDAQ:CURX) last announced its earnings results on Monday, March 30th. The company reported ($0.12) earnings per share for the quarter.

Institutional Investors Weigh In On Curanex Pharmaceuticals

An institutional investor recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC purchased a new position in Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.